Clinical Trials
92 trialsNCT00690560 2026-05-22
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Phase 2 Completed
NCT01359592 2025-06-17
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00577278 2024-02-16
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Phase 2 Completed
NCT00031642 2023-12-27
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
University of Nebraska
Phase 1/2 Completed
NCT01827605 2023-12-14
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT00168727 2023-08-23
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed
NCT01811368 2022-11-30
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Unknown
NCT00493467 2022-09-15
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00322218 2022-01-19
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00070018 2022-01-11
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
NCT01510184 2021-12-16
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01549886 2021-10-04
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT01662102 2021-10-04
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01448928 2021-10-01
ZEVALIN-DUI
Spectrum Pharmaceuticals, Inc
Completed
NCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00591630 2021-02-02
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00058422 2020-11-12
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00491491 2020-08-31
Zevalin-beam for Aggressive Lymphoma
Sheba Medical Center
Phase 3 Completed
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00662948 2020-04-28
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
PETHEMA Foundation
Phase 2 Completed
NCT00582166 2019-12-13
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
University of Wisconsin, Madison
Phase 2 Terminated
NCT01493479 2019-10-15
FIZZ
The Christie NHS Foundation Trust
Phase 2 Completed
NCT00372905 2019-09-04
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Northwestern University
Phase 1/2 Terminated
NCT00732498 2019-09-04
ESHAP
University of Arizona
Phase 2 Completed
NCT00089284 2019-08-14
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Northwestern University
Phase 1/2 Terminated
NCT00392691 2019-05-15
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Phase 1 Completed
NCT01686165 2018-08-28
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
Phase 2 Completed
NCT00012298 2018-08-09
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00695409 2018-07-06
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00477815 2018-05-14
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00689169 2018-03-07
ZBEAM2
Lymphoma Study Association
Phase 2 Completed
NCT00073957 2018-01-23
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00110149 2017-11-21
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Terminated
NCT00644371 2017-03-27
Z-RIC-Allo
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT01207765 2017-03-20
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Tufts Medical Center
Phase 2 Terminated
NCT00334438 2016-12-23
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00607854 2016-10-05
ZEVALLO
University Hospital, Bordeaux
Phase 2 Completed
NCT00062114 2016-07-06
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01446562 2016-06-17
ZEVISS
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00414089 2016-02-15
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL
AHS Cancer Control Alberta
Phase 2 Withdrawn
NCT00646750 2016-02-15
Z-BEAM LDGGB
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn